Hyloris Developmentsen Sa (HYL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hyloris Developmentsen Sa (HYL) has a cash flow conversion efficiency ratio of -0.058x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.67 Million ≈ $-1.95 Million USD) by net assets (€28.89 Million ≈ $33.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HYL equity to assets ratio to measure how much of total assets are equity-financed.
Hyloris Developmentsen Sa - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Hyloris Developmentsen Sa's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HYL capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Hyloris Developmentsen Sa Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hyloris Developmentsen Sa ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
S-Oil Corp Pref
KO:010955
|
0.103x |
|
Canton Strategic Holdings, Inc.
NASDAQ:CNTN
|
-0.016x |
|
Daewon Sanup Co. Ltd
KQ:005710
|
-0.021x |
|
Lucky Cement Co
TW:1108
|
0.039x |
|
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
|
-0.151x |
|
Nextronics Engineering
TWO:8147
|
0.112x |
|
PetroVietnam General Services Corp
VN:PET
|
-0.330x |
|
Elanor Commercial Property Fund
AU:ECF
|
0.066x |
Annual Cash Flow Conversion Efficiency for Hyloris Developmentsen Sa (2017–2024)
The table below shows the annual cash flow conversion efficiency of Hyloris Developmentsen Sa from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see HYL market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €32.14 Million ≈ $37.58 Million |
€-6.70 Million ≈ $-7.84 Million |
-0.209x | +36.39% |
| 2023-12-31 | €39.07 Million ≈ $45.68 Million |
€-12.81 Million ≈ $-14.97 Million |
-0.328x | -37.19% |
| 2022-12-31 | €55.05 Million ≈ $64.35 Million |
€-13.15 Million ≈ $-15.38 Million |
-0.239x | -2.08% |
| 2021-12-31 | €48.06 Million ≈ $56.18 Million |
€-11.25 Million ≈ $-13.15 Million |
-0.234x | -202.53% |
| 2020-12-31 | €59.06 Million ≈ $69.05 Million |
€-4.57 Million ≈ $-5.34 Million |
-0.077x | -117.28% |
| 2019-12-31 | €-10.19 Million ≈ $-11.91 Million |
€-4.56 Million ≈ $-5.33 Million |
0.448x | -62.78% |
| 2018-12-31 | €-4.46 Million ≈ $-5.22 Million |
€-5.37 Million ≈ $-6.28 Million |
1.203x | +219.08% |
| 2017-12-31 | €-4.29 Million ≈ $-5.01 Million |
€-1.62 Million ≈ $-1.89 Million |
0.377x | -- |
About Hyloris Developmentsen Sa
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more